Update on the treatment of metastatic renal cell carcinoma.
Ontology highlight
ABSTRACT: Metastatic renal cell cancer (mRCC) management has undergone a paradigm shift in recent decades. The first revolution came with the emergence of vascular endothelial growth factor inhibitors; there was a second wave with the unprecedented success of checkpoint inhibitors, and then the latest approach, which is becoming the new care standard in mRCC, of combining these two strategies in different ways. Updated results of Checkmate-214 after 42 mo of follow-up were consistent with previously published results showing the superiority of nivolumab/ipilimumab over sunitinib in progression free survival (PFS), overall survival (OS), and objective response rate (ORR) in intermediate and high-risk patients. However, several studies presented at the American Society of Clinical Oncology 2020 sugges
SUBMITTER: Medina Lopez RA
PROVIDER: S-EPMC8790301 | biostudies-literature | 2022 Jan
REPOSITORIES: biostudies-literature
ACCESS DATA